Skip to content

Defining the Functional and Neuro-Protective Potential of ACTHAR in Acute Optic Neuritis

Potential Neuroprotection With ACTHAR Following Acute Optic Neuritis

Status
Completed
Phases
Early Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01987167
Acronym
ACHTAR
Enrollment
25
Registered
2013-11-19
Start date
2013-11-30
Completion date
2016-12-31
Last updated
2017-08-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Optic Neuritis

Keywords

acute optic neuritis

Brief summary

The goal of the study is to determine the earliest structural changes in the optic nerve during the acute event and during the twelve months of recovery following Acthar treatment.

Detailed description

Determine the earliest structural changes in the optic nerve during the acute event and during the twelve months of recovery following Acthar treatment.

Interventions

DRUGACTHAR

Injectable Gel

Sponsors

Mallinckrodt
CollaboratorINDUSTRY
Neuro-Ophthalmologic Associates, PC
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* unilateral acute demyelinating optic neuritis * Able to provide informed consent * age 18 or older * can perform the above listed electrophysiologic diagnostic testing * can perform high and low contrast visual acuity and visual field perimetry

Exclusion criteria

* prior diagnosis of remitting/relapsing multiple sclerosis(RRMS) * secondary progressive MS(SPMS) * primary progressive MS (PPMS) * undergoing treatment with medications approve for treatment of RRMS(except corticosteroids for a condition not involving central nervous system demyelination) * prior diagnosis of systemic lupus erythematosis * mixed connective tissue disease * vasculitis * sarcoidosis * neuro-myelitis optica

Design outcomes

Primary

MeasureTime frameDescription
Neuro-protection12 monthsFunctional with low contrast visual acuity in bothe the eye acutely affected by optic neuritis and the clinically unaffected eye.

Secondary

MeasureTime frameDescription
Preservation of retinal nerve fiber layer.12 monthsTo define the objective (micron thickness, volumetric analysis) and subjective (histopathological changes) of spectral domain optical coherence tomography (SD-OCT) at the time of clinical presentation of acute optic neuritis and during 6 months of recovery following ACTHAR treatment.

Other

MeasureTime frameDescription
Preservation and/or restoration of electrophysiological parameters for patients with acute optic neuritis.12 monthsTo define the electrophysiological changes at the onset and following an acute event of optic neuritis with Multifocal electroretinography(mERG) and visual evoked potentials (VEP)
Structural, Physiological and Metabolic changes during an acute event of optic neuritis12 monthsto determine the earliest structural, physiological, and metabolic changes in the optic nerve during an acute event of demyelinating optic neuritis and the natural history of these changes over 6 months.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026